Richard J. O'Reilly, MD -- Chair, Department of Pediatrics; Chief, Pediatric Bone Marrow Transplant Service; Claire L. Tow Chair in Pediatric Oncology Research

Richard J. O'Reilly, MD

Bone Marrow Transplant Specialist

Titles

Claire L. Tow Chair in Pediatric Oncology Research

Clinical Expertise

Pediatric Oncology; Allogeneic and Autologous Bone Marrow and Peripheral Blood Stem Cell Transplantation; Congenital and Acquired Diseases of Hematopoiesis and Immunity

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. O'Reilly accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 9/1/23)

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO

First Health

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Medicare Part A&B (traditional Medicare)

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, University of Rochester School of Medicine

Residencies

Pediatrics - Children's Hospital Medical Center

Fellowships

Infectious Disease - Children's Hospital Medical Center/Beth Israel Hospital

Board Certifications

Pediatrics

As former Chair of the Department of Pediatrics, I oversaw all aspects of the clinical, medical education, and research endeavors the department is privileged to provide. My clinical expertise is in bone marrow transplantation and the treatment of children with congenital and acquired immunological deficiencies. I have particular expertise in treating genetic diseases that impair hematopoiesis — the formation of blood cells — as well as pediatric leukemias. I am also an authority on transplantation immunology and cellular therapies.

Read more

I’ve always been fascinated by the immunology of transplantation and our ability to use this approach to cure diseases. I was involved in the first transplant of bone marrow from an unrelated donor to a patient in 1973. This opened the possibility of a transplant to the majority of patients who lack a matched brother or sister. Since then, we have greatly refined this approach. In fact most of the transplants we perform are now from unrelated donors.

I also conduct laboratory and clinical research, and have led national studies of new therapies for children with genetic immunodeficiencies and both adults and children with leukemia and other life-threatening blood diseases. I and my colleagues developed and introduced methods for removing T cells from the donor’s transplant. (T cells are the white blood cells that can attack the tissues of the patient and cause a complication called graft-versus-host disease [GvHD]). This approach has proven to be an effective way to prevent GvHD, and has allowed us to transplant marrow from genetically half-matched donors, such as a mother or father, without causing severe or fatal GvHD. We’ve also developed and introduced in clinical trial, new immune cell therapies to manage other potential complications of transplantation, such as Epstein-Barr-virus lymphomas and cytomegalovirus infections. Today there is no more “boy in the bubble,” thanks to the advances we’ve made in bone marrow transplantation.

My fellow scientists and I are now developing cellular therapies that could be used to enhance the resistance of bone marrow transplant recipients to not only serious infections but also their underlying cancers. We’re aiming to create novel systems to elicit an immune response in the patient against infectious organisms or residual cancer cells.

I am privileged to work with a dedicated and experienced team of professionals who have the capacity to assess clinical challenges and develop innovative solutions. We share a passion for delivering good medicine. We’ve also developed support systems for patients and their families that are second to none.

I have shared my experience and knowledge with fellows and residents, many of whom have gone on to establish bone marrow transplant programs at institutions around the world. I am past-President and currently a member of the Board of the Damon Runyon-Walter Winchell Cancer Fund, and on the Board of the Children’s Oncology Society of New York, which runs the local Ronald McDonald House. I have won several awards for my work, including honors from the American Society of Clinical Oncology, the Society of Translational Oncology, the American Society for Blood and Marrow Transplantation, and Leiden University in The Netherlands.

Awards and Honors

  • Castle Connolly: America's Top Doctors (2023)
  • Castle Connolly: New York Magazine Top Doctors (2002-2016)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Pediatrics doctors

See all Bone Marrow Transplant Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

View Dr. O'Reilly's Lab

Dinsmore R, Kirkpatrick D, Flomenberg N, et al. Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia. Blood 1983; 62 :381

Shank B, Chu FC, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 1983; 9 :1607

Brochstein JA, Kernan NA, Groshen S, et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987; 317 :1618

Read more

Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998 Feb 1;91(3):1083-90 1998; 91 :1083

Boulad F, Steinherz P, Reyes B, et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17 :197

Walters MC, Sullivan KM, O’Reilly RJ, et al. Bone marrow transplantation for thalassemia. The USA experience.. Am J Pediatr Hematol Oncol 1994; 16 :11

Boulad F, Giardina P, Gillio A, et al. Bone marrow transplantation for homozygous beta-thalassemia. The Memorial Sloan Kettering Cancer Center experience. Ann N Y Acad Sci 1998; 850 :498

Gillio AP, Boulad F, Small TN, et al. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Biol Blood Marrow Transplant 1997; 3 :18

O’Reilly RJ, Dupont B, Pahwa S, et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977; 297 :1311

O’Reilly RJ, Kapoor N, Pollack M, et al. Reconstitution of immunologic function in a patient with severe combined immunodeficiency following transplantation of marrow from an HLA-A,B,C nonidentical but MLC-compatible paternal donor. Transplant Proc 1979; 11 :1934

Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983; 61 :341

O’Reilly RJ, Keever CA, Small TN, et al. The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease. Immunodefic Rev 1989; 1 :273

Brochstein JA, Gillio AP, Ruggiero M, et al. Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for correction of Wiskott-Aldrich syndrome. J Pediatr 1991; 119 :907

Castro-Malaspina H, Childs B, Laver J, et al. Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia. Int J Radiat Oncol Biol Phys 1994; 29 :847

 

Publications on PubMed

Visit PubMed for a full listing of Dr. O'Reilly’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Richard J. O'Reilly discloses the following relationships and financial interests:

  • Atara Biotherapeutics
    Intellectual Property Rights; Provision of Services
  • Damon Runyon Cancer Research Foundation
    Fiduciary Role/Position
  • Ronald McDonald House New York
    Fiduciary Role/Position

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures